AMAL vs BRK-B

AMAL's Piotroski F-Score of 4/9 indicates a weak financial health profile, signaling potential operational inefficiencies or instability despite solid profitability metrics. The absence of an Altman Z-Score raises concern about default risk, especially given the lack of available leverage and liquidity data. While the stock trades below its intrinsic value of $80.65 and Graham Number of $45.21, suggesting undervaluation, the current price of $38.10 is significantly below both benchmarks, implying either deep value or market skepticism. Strong earnings growth (11.1% YoY) and consistent beat rates (3/4 in last 4 quarters) support future potential, but technical trends and insider selling undermine near-term momentum.

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.